Get the Daily Brief
Latest Biotech News
Checkpoint diagnostics expand: Guardant360 Liquid CDx gets FDA approval
Guardant Health received FDA approval for its upgraded Guardant360 Liquid CDx, a blood-based comprehensive genomic test designed to support treatment selection in advanced cancer. The company said...
Targeted oncology diagnostics: FoundationOne CDx approved for Tepmetko across tissue and liquid
FDA approved Foundation Medicine’s FoundationOne CDx as a companion diagnostic for EMD Serono’s Tepmetko (tepotinib) to identify metastatic NSCLC patients with MET exon 14 skipping alterations....
Clinical failure: LRRK2-targeting Parkinson’s pill does not slow disease
Biogen and Denali Therapeutics said their experimental Parkinson’s therapy targeting LRRK2 failed to slow disease progression in a randomized trial. The study randomized 648 adults with...
AI platforms move from pilots to enterprise integration in Big Pharma
Bristol Myers Squibb announced a partnership with Anthropic to deploy Claude across its global operations, with plans to integrate the system across research, clinical development, manufacturing,...
AI-enabled protein design targets GPCR conformations
A study led by researchers at the University of Washington Institute for Protein Design and Skape Bio reported AI-driven de novo protein design of miniproteins that can switch GPCRs on or off with...
Obesity clinical pipeline: Lilly retatrutide Phase 3 top-line results and longer-term data direction
Eli Lilly reported top-line Phase 3 results for retatrutide in obesity, describing weight loss outcomes up to 28% at the highest tested doses over 80 weeks. The company also said the dataset shows...
Venture funding for inflammation and immunology: cAMPfield raises Series A
cAMPfield Therapeutics, a San Diego biotech working on inflammatory and immunology medicines, raised an $180 million Series A, according to the report. The company’s financing highlights continued...
Growth-stage company deal: InSphero acquires PhenoVista Biosciences for imaging and phenotypic assays
InSphero announced it has acquired PhenoVista Biosciences, a cell-based assay services provider specializing in high-content imaging and phenotypic assay technologies. The deal is expected to...
Frontline lung cancer efficacy readouts for ADC–immunotherapy combos
Merck and Kelun-Biotech reported Phase 3 results at ASCO 2026 showing that the TROP2-directed sacituzumab tirumotecan (sac-TMT) added to Keytruda cut the risk of disease progression or death by...
FDA expands companion diagnostic access for MET exon 14 NSCLC
The FDA approved Foundation Medicine’s FoundationOne CDx as a companion diagnostic for EMD Serono’s Tepmetko (tepotinib) to identify metastatic NSCLC patients with MET exon 14 skipping...
Regulatory compliance action on GLP-1 API import safeguards
FDA issued a warning letter to Harbin Jixianglong Biotech after inspectors alleged the company attempted to circumvent recently introduced GLP-1 receptor agonist import restrictions. The regulator...
Parkinson’s targeted LRRK2 therapy fails to hit primary objective
Biogen and Denali Therapeutics disclosed that their experimental Parkinson’s therapy targeting LRRK2 failed to slow the degenerative disease in a randomized trial. The study enrolled 648 adults...
Obesity triple-agonist retatrutide posts new Phase 3 weight-loss results
Eli Lilly reported new Phase 3 top-line results for retatrutide in obesity, with all tested doses meeting primary and key secondary endpoints and driving average weight loss in the range of 19% to...
FDA approves expanded ctDNA liquid genomic profiling for multiple cancer CDx uses
Guardant Health received FDA approval for its upgraded Guardant360 Liquid CDx test, providing broader genomic and epigenomic profiling from a single blood draw. The company said the test covers a...
Biotech corporate: Seer board rejects renewed takeover offer
Seer said its board unanimously rejected a renewed takeover bid from investor group led by Bradley Radoff and Michael Torok, despite the offer structure increasing contingent value terms. The...
FDA clearance for allogeneic CAR-T trial in autoimmune disease
Hangzhou Qihan Biotech obtained FDA IND clearance for QT-019C, a universal allogeneic CAR T-cell therapy engineered to target both CD19 and BCMA for autoimmune diseases. The company said the...
Lilly continues genetic-medicine M&A with Engage Bio acquisition
Eli Lilly agreed to acquire Engage Biologics in a deal worth up to $202 million, adding preclinical non-viral DNA delivery capabilities to its genetic medicines pipeline. Engage’s platform, called...
Biotech venture: RA Capital-backed SPAC raises $75M for a biotech merger
RA Capital Management’s blank-check entity Research Alliance III raised $75 million in its IPO to merge into an existing biotechnology company. The SPAC sold 7.5 million shares at $10 each and...
Oncology trial readouts at ASCO26
Multiple oncology readouts tied to ASCO26 are pointing to expanding options across lung and head-and-neck cancer, with companies using combination strategies aimed at both efficacy and...
Next-gen obesity pipeline moves toward regulatory milestones
Eli Lilly’s next-generation obesity franchise advanced further with new Phase 3 topline data for retatrutide, reinforcing the company’s competitive positioning versus both GLP-1 and dual-agonist...